WendyJoLevinMDMS

VP Clinical Development Fate Therapeutics

Dr. Levin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
10646 Science Center Dr
CB10
San Diego, CA 92121
Phone+1 858-622-8019

Fax+1 877-481-5208

University of WashingtonFellowship, Hematology and Medical Oncology, 2001 - 2004
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1998 - 2001
St. George's University School of MedicineClass of 1998

PubMed

9041 citations
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon, Gary M. Clark, Steven G. Wong, Wendy J. Levin, Axel Ullrich
Science. 1987-01-09
98 citations
Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies
Dana D. Hu-Lowe, Enhong Chen, Lianglin Zhang, Katherine D. Watson, Patrizia Mancuso
Cancer Research. 2011-02-15
5519 citations
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
Dennis J. Slamon, William Godolphin, Lovell A. Jones, John A. Holt, Steven G. Wong
Science. 1989-05-12

New Data Demonstrates Novel Genomic Technology Provides Ultra-Sensitive Detection of Gene Fusions from RNAOctober 18th, 2022
New California Law Increases Access to Biomarker Testing for Late-Stage Cancer PatientsOctober 13th, 2021
Winning the Race to Fight Lung Cancer? Medtech Company with RTP Lab Says It Can Speed up Biomarker Test at Lower CostsSeptember 8th, 2023
Join now to see all